JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on September 20, 2005; DOI: 10.1124/jpet.105.092874


0022-3565/06/3161-304-314$20.00
JPET 316:304-314, 2006
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.105.092874v1
jpet.105.092874v2
316/1/304    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lemarie, A.
Right arrow Articles by Vernhet, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lemarie, A.
Right arrow Articles by Vernhet, L.

TOXICOLOGY

Arsenic Trioxide Induces Apoptosis of Human Monocytes during Macrophagic Differentiation through Nuclear Factor-{kappa}B-Related Survival Pathway Down-Regulation

Anthony Lemarie, Claudie Morzadec, Delphine Mérino, Olivier Micheau, Olivier Fardel, and Laurent Vernhet

Institut National de la Sante et de la Recherche Medicale U620, Détoxication et Réparation Tissulaire, Université de Rennes 1, Rennes, France (A.L., C.M., O.F., L.V.); Institut National de la Sante et de la Recherche Medicale U517, Mort Cellulaire et Cancer, Facultés de Médecine et Pharmacie, Dijon, France (D.M., O.M.); and Laboratoire d'Hématologie-Immunologie, Centre Hospitalier Universitaire Pontchaillou, Rennes, France (O.F.)

Arsenic trioxide (As2O3) is known to be toxic toward leukemia cells. In this study, we determined its effects on survival of human monocytic cells during macrophagic differentiation, an important biological process involved in the immune response. As2O3 used at clinically relevant pharmacological concentrations induced marked apoptosis of human blood monocytes during differentiation with either granulocyte-macrophage colony-stimulating factor or macrophage colony-stimulating factor. Apoptosis of monocytes was associated with increased caspase activities and decreased DNA binding of p65 nuclear factor-{kappa}B (NF-{kappa}B); like As2O3, the selective NF-{kappa}B inhibitor (E)-3-[(4-methylphenyl)-sulfonyl]-2-propenenitrile (Bay 11-7082) strongly reduced survival of differentiating monocytes. The role of NF-{kappa}B in arsenic toxicity was also studied in promonocytic U937 cells during phorbol 12-myristate 13-acetate-induced macrophagic differentiation. In these cells, As2O3 first reduced DNA binding of p65 NF-{kappa}B and subsequently induced apoptosis. In addition, overexpression of the p65 NF-{kappa}B subunit, following stable infection with a p65 retroviral expressing vector, increased survival of As2O3-treated U937 cells. As2O3 specifically decreased protein levels of X-linked inhibitor of apoptosis protein and FLICE-inhibitory protein, two NF-{kappa}B-regulated genes in both U937 cells and blood monocytes during their differentiations. Finally, As2O3 was found to inhibit macrophagic differentiation of monocytic cells when used at cytotoxic concentrations; however, overexpression of the p65 NF-{kappa}B subunit in U937 cells reduced its effects toward differentiation. In contrast to monocytes, well differentiated macrophages were resistant to low concentrations of As2O3. Altogether, our study demonstrates that clinically relevant concentrations of As2O3 induced marked apoptosis of monocytic cells during in vitro macrophagic differentiation likely through inhibition of NF-{kappa}B-related survival pathways.


Received July 19, 2005; accepted September 14, 2005.

Address correspondence to: Laurent Vernhet, Unité INSERM U620, Dé-toxication et Réparation Tissulaire, Faculté des Sciences Pharmaceutiques et Biologiques, Université de Rennes 1, 2 avenue du Pr. Léon Bernard, 35043 Rennes, France. E-mail: laurent.vernhet{at}rennes.inserm.fr




This article has been cited by other articles:


Home page
J. Leukoc. Biol.Home page
F. Binet and D. Girard
Novel human neutrophil agonistic properties of arsenic trioxide: involvement of p38 mitogen-activated protein kinase and/or c-jun NH2-terminal MAPK but not extracellular signal-regulated kinases-1/2
J. Leukoc. Biol., December 1, 2008; 84(6): 1613 - 1622.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Lemarie, E. Bourdonnay, C. Morzadec, O. Fardel, and L. Vernhet
Inorganic Arsenic Activates Reduced NADPH Oxidase in Human Primary Macrophages through a Rho Kinase/p38 Kinase Pathway
J. Immunol., May 1, 2008; 180(9): 6010 - 6017.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Lemarie, C. Morzadec, E. Bourdonnay, O. Fardel, and L. Vernhet
Human macrophages constitute targets for immunotoxic inorganic arsenic.
J. Immunol., September 1, 2006; 177(5): 3019 - 3027.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.